Private GP in London
previous arrow
next arrow

A recent study reviewed 58 epidemiological studies worldwide. It found that five years of menopausal hormone therapy (MHT), starting at age 50 years, would increase breast cancer incidence from age 50 to 69 years by about one additional case in every 50 users of oestrogen plus daily progestogen MHT, one in every 70 users of oestrogen plus intermittent progestogen MHT, and one in every 200 users of oestrogen-only MHT. Furthermore, it showed that some excess risk persists for more than 10 years after ceasing MHT.

The report was published by  Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice for prescribers of hormone replacement therapy (HRT), following the publication of new data in The Lancet.